vs
Side-by-side financial comparison of GOLDEN ENTERTAINMENT, INC. (GDEN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $155.6M, roughly 1.1× GOLDEN ENTERTAINMENT, INC.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -5.5%, a 7.1% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -5.2%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -5.4%).
Golden Entertainment, Inc. is an American gambling company based in Enterprise, Nevada that operates casinos and taverns. It was formed in 2015 by the merger of Golden Gaming and Lakes Entertainment. It is the largest tavern operator in Nevada. In October 2017, the company completed an $850 million acquisition of American Casino & Entertainment Properties. The company now has eight casino resorts, all located in Southern Nevada.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GDEN vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $155.6M | $177.4M |
| Net Profit | $-8.5M | $2.9M |
| Gross Margin | 92.5% | — |
| Operating Margin | -1.5% | 3.9% |
| Net Margin | -5.5% | 1.6% |
| Revenue YoY | -5.2% | 5.0% |
| Net Profit YoY | -386.0% | — |
| EPS (diluted) | $-0.31 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $155.6M | $196.9M | ||
| Q3 25 | $154.8M | $179.5M | ||
| Q2 25 | $163.6M | $181.1M | ||
| Q1 25 | $160.8M | $168.9M | ||
| Q4 24 | $164.2M | $187.3M | ||
| Q3 24 | $161.2M | $168.6M | ||
| Q2 24 | $167.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-8.5M | — | ||
| Q3 25 | $-4.7M | $5.4M | ||
| Q2 25 | $4.6M | $-4.8M | ||
| Q1 25 | $2.5M | $4.8M | ||
| Q4 24 | $3.0M | — | ||
| Q3 24 | $5.2M | $-143.5M | ||
| Q2 24 | $623.0K | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 92.5% | 79.5% | ||
| Q3 25 | 92.8% | 80.9% | ||
| Q2 25 | 93.1% | 77.4% | ||
| Q1 25 | 92.7% | 79.7% | ||
| Q4 24 | 96.3% | 78.7% | ||
| Q3 24 | 93.0% | 76.9% | ||
| Q2 24 | 93.2% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -1.5% | 1.2% | ||
| Q3 25 | 0.6% | 3.5% | ||
| Q2 25 | 7.3% | 4.7% | ||
| Q1 25 | 6.9% | 1.2% | ||
| Q4 24 | 7.1% | 13.2% | ||
| Q3 24 | 4.2% | -82.8% | ||
| Q2 24 | 8.1% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -5.5% | — | ||
| Q3 25 | -3.0% | 3.0% | ||
| Q2 25 | 2.8% | -2.7% | ||
| Q1 25 | 1.6% | 2.8% | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 3.2% | -85.1% | ||
| Q2 24 | 0.4% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.31 | $0.05 | ||
| Q3 25 | $-0.18 | $0.12 | ||
| Q2 25 | $0.17 | $-0.11 | ||
| Q1 25 | $0.09 | $0.10 | ||
| Q4 24 | $0.14 | $0.38 | ||
| Q3 24 | $0.18 | $-3.11 | ||
| Q2 24 | $0.02 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $55.3M | $144.3M |
| Total DebtLower is stronger | $426.6M | — |
| Stockholders' EquityBook value | $420.9M | $653.9M |
| Total Assets | $1.0B | $1.2B |
| Debt / EquityLower = less leverage | 1.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $55.3M | $238.4M | ||
| Q3 25 | $58.3M | $246.3M | ||
| Q2 25 | $52.3M | $445.9M | ||
| Q1 25 | $50.5M | $493.6M | ||
| Q4 24 | $57.7M | $484.6M | ||
| Q3 24 | $68.6M | $453.8M | ||
| Q2 24 | $88.6M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $426.6M | $372.2M | ||
| Q3 25 | $417.3M | $376.7M | ||
| Q2 25 | $423.3M | $580.5M | ||
| Q1 25 | $399.3M | $583.4M | ||
| Q4 24 | $405.3M | $585.3M | ||
| Q3 24 | $386.3M | — | ||
| Q2 24 | $388.2M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $420.9M | $693.1M | ||
| Q3 25 | $434.2M | $727.2M | ||
| Q2 25 | $443.3M | $757.8M | ||
| Q1 25 | $462.0M | $798.5M | ||
| Q4 24 | $474.2M | $778.3M | ||
| Q3 24 | $513.1M | $749.6M | ||
| Q2 24 | $539.0M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.0B | $1.3B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.1B | $1.6B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.2B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.01× | 0.54× | ||
| Q3 25 | 0.96× | 0.52× | ||
| Q2 25 | 0.95× | 0.77× | ||
| Q1 25 | 0.86× | 0.73× | ||
| Q4 24 | 0.85× | 0.75× | ||
| Q3 24 | 0.75× | — | ||
| Q2 24 | 0.72× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.2M | — |
| Free Cash FlowOCF − Capex | $-4.4M | — |
| FCF MarginFCF / Revenue | -2.8% | — |
| Capex IntensityCapex / Revenue | 9.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $35.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $10.2M | $43.7M | ||
| Q3 25 | $26.9M | $60.8M | ||
| Q2 25 | $17.4M | $12.0M | ||
| Q1 25 | $28.6M | $35.5M | ||
| Q4 24 | $22.5M | $33.1M | ||
| Q3 24 | $22.5M | $53.9M | ||
| Q2 24 | $21.5M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-4.4M | $43.5M | ||
| Q3 25 | $19.3M | $57.0M | ||
| Q2 25 | $4.0M | $9.3M | ||
| Q1 25 | $16.6M | $26.9M | ||
| Q4 24 | $14.3M | $31.0M | ||
| Q3 24 | $14.7M | $49.8M | ||
| Q2 24 | $3.9M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -2.8% | 22.1% | ||
| Q3 25 | 12.5% | 31.7% | ||
| Q2 25 | 2.4% | 5.1% | ||
| Q1 25 | 10.4% | 15.9% | ||
| Q4 24 | 8.7% | 16.6% | ||
| Q3 24 | 9.1% | 29.6% | ||
| Q2 24 | 2.3% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 9.4% | 0.1% | ||
| Q3 25 | 4.9% | 2.2% | ||
| Q2 25 | 8.2% | 1.5% | ||
| Q1 25 | 7.4% | 5.1% | ||
| Q4 24 | 5.0% | 1.1% | ||
| Q3 24 | 4.9% | 2.4% | ||
| Q2 24 | 10.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 3.76× | — | ||
| Q1 25 | 11.43× | 7.37× | ||
| Q4 24 | 7.57× | — | ||
| Q3 24 | 4.36× | — | ||
| Q2 24 | 34.51× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GDEN
| Nevada Casino Resorts | $90.2M | 58% |
| Nevada Locals Casinos | $37.4M | 24% |
| Nevada Taverns | $27.7M | 18% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
